JP2024516665A - 敗血症の早期検出のためのプレセプシンマーカーパネル - Google Patents

敗血症の早期検出のためのプレセプシンマーカーパネル Download PDF

Info

Publication number
JP2024516665A
JP2024516665A JP2023566594A JP2023566594A JP2024516665A JP 2024516665 A JP2024516665 A JP 2024516665A JP 2023566594 A JP2023566594 A JP 2023566594A JP 2023566594 A JP2023566594 A JP 2023566594A JP 2024516665 A JP2024516665 A JP 2024516665A
Authority
JP
Japan
Prior art keywords
biomarker
subject
amount
biomarkers
assessing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516665A5 (https=
Inventor
グリューネバルト フェリクス
ヨハン ラウル イェガー ビクトール
クラマー マルティン
シュッツ フィリップ
フォン ホルタイ マリア
ウェーバー スティーブン
ベグマイアー ハイケ
ビエンヒュース－テレン ウルズラ－ヘンリーケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2024516665A publication Critical patent/JP2024516665A/ja
Publication of JP2024516665A5 publication Critical patent/JP2024516665A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023566594A 2021-04-30 2022-04-29 敗血症の早期検出のためのプレセプシンマーカーパネル Pending JP2024516665A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21171495 2021-04-30
EP21171495.1 2021-04-30
PCT/EP2022/061587 WO2022229442A2 (en) 2021-04-30 2022-04-29 Presepsin marker panels for early detection of sepsis

Publications (2)

Publication Number Publication Date
JP2024516665A true JP2024516665A (ja) 2024-04-16
JP2024516665A5 JP2024516665A5 (https=) 2025-05-09

Family

ID=75746437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566594A Pending JP2024516665A (ja) 2021-04-30 2022-04-29 敗血症の早期検出のためのプレセプシンマーカーパネル

Country Status (5)

Country Link
US (1) US20240230672A1 (https=)
EP (1) EP4330682A2 (https=)
JP (1) JP2024516665A (https=)
CN (1) CN117321419A (https=)
WO (1) WO2022229442A2 (https=)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501521A (ja) * 2005-07-13 2009-01-22 ベス イスラエル ディーコネス メディカル センター 炎症応答を診断および処置する方法
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
JP2013527453A (ja) * 2010-05-17 2013-06-27 エフ．ホフマン−ラ ロシュ アーゲー 急性炎症における生存および回復を推定するためのｇｄｆ−１５に基づく手段および方法
US20140377777A1 (en) * 2011-12-08 2014-12-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2017506510A (ja) * 2014-02-11 2017-03-09 イギリス国Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｓｔａｔｅ Ｆｏｒ Ｄｅｆｅｎｃｅ Ｉｎ Ｈｅｒ Ｂｒｉｔａｎｎｉｃ Ｍａｊｅｓｔｙ’Ｓ Ｇｏｖｅｒｎｍｅｎｔ Ｏｆ Ｔｈｅ Ｕｎｅｔｅｄ Ｋｉｎｇｄｏｍ Ｏｆ Ｇｒｅａｔ Ｂｒｉｔａｉｎ Ａｎｄ Ｎｏｒｔｈｅｒｎ Ｉｒｅｌａｎｄ 敗血症の発症を予測するための装置、キット及び方法
JP2018532114A (ja) * 2015-10-08 2018-11-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 手術前に測定した際にａｋｉのリスクを予測するためのｉｇｆｂｐ７
US20200225248A1 (en) * 2017-05-31 2020-07-16 B.R.A.H.M.S Gmbh Mmp-8 as a marker for identifying infectious disease
JP2021507236A (ja) * 2017-12-20 2021-02-22 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング プロカルシトニンと中間領域プロアドレノメデュリンを使用したリスク評価と患者管理のためのワークフロー

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
JP2002543841A (ja) 1999-05-17 2002-12-24 バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー ＴＧＦ−βスーパーファミリーの新規のメンバーであるＧＤＦ―１５の神経保護特性
CA2476597C (en) 2002-02-28 2011-05-17 Metanomics Gmbh & Co. Kgaa Mass spectrometry method for analysing mixtures of substances
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
CN103123359B (zh) 2007-08-03 2015-07-29 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用
RU2016112915A (ru) 2013-09-05 2017-10-09 Эф-Ай-Оу Корпорейшн Биомаркеры для раннего выявления критической или угрожающей жизни ответной реакции на заболевание и/или ответной реакции на лечение

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501521A (ja) * 2005-07-13 2009-01-22 ベス イスラエル ディーコネス メディカル センター 炎症応答を診断および処置する方法
JP2013527453A (ja) * 2010-05-17 2013-06-27 エフ．ホフマン−ラ ロシュ アーゲー 急性炎症における生存および回復を推定するためのｇｄｆ−１５に基づく手段および方法
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
US20140377777A1 (en) * 2011-12-08 2014-12-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2017506510A (ja) * 2014-02-11 2017-03-09 イギリス国Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｓｔａｔｅ Ｆｏｒ Ｄｅｆｅｎｃｅ Ｉｎ Ｈｅｒ Ｂｒｉｔａｎｎｉｃ Ｍａｊｅｓｔｙ’Ｓ Ｇｏｖｅｒｎｍｅｎｔ Ｏｆ Ｔｈｅ Ｕｎｅｔｅｄ Ｋｉｎｇｄｏｍ Ｏｆ Ｇｒｅａｔ Ｂｒｉｔａｉｎ Ａｎｄ Ｎｏｒｔｈｅｒｎ Ｉｒｅｌａｎｄ 敗血症の発症を予測するための装置、キット及び方法
JP2018532114A (ja) * 2015-10-08 2018-11-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 手術前に測定した際にａｋｉのリスクを予測するためのｉｇｆｂｐ７
US20200225248A1 (en) * 2017-05-31 2020-07-16 B.R.A.H.M.S Gmbh Mmp-8 as a marker for identifying infectious disease
JP2021507236A (ja) * 2017-12-20 2021-02-22 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング プロカルシトニンと中間領域プロアドレノメデュリンを使用したリスク評価と患者管理のためのワークフロー

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALICE NICOLETA DRAGOESCU ET AL.: ""Presepsin as a Potential Prognostic Marker for Sepsis According to Actual Practice Guidelines"", JOURNAL OF PERSONALIZED MEDICINE, vol. 11, no. 1, JPN6026013182, 22 December 2020 (2020-12-22), pages 2, ISSN: 0005834595 *
F． MEARELLI ET AL.: ""Sepsis outside intensive care unit: the other side of the coin"", INFECTION, vol. 43, no. 1, JPN6026013177, 11 August 2014 (2014-08-11), pages 1 - 11, ISSN: 0005834591 *
FREDERIK FRUERGAARD LARSEN ET AL.: ""Novel biomarkers for sepsis: A narrative review"", EUROPEAN JOURNAL OF INTERNAL MEDICINE, vol. 45, JPN6026013178, November 2017 (2017-11-01), pages 46 - 50, ISSN: 0005834592 *
JIABAO LI ET AL.: ""Association between elevation of plasma biomarkers and monocyte dysfunction and their combination", INNATE IMMUNITY, vol. 26, no. 6, JPN6026013179, 26 May 2020 (2020-05-26), pages 514 - 527, ISSN: 0005834593 *
LEILA B. GIRON ET AL.: ""Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients"", FRONTIERS IN IMMUNOLOGY, vol. 12, JPN6026013181, 16 November 2020 (2020-11-16), ISSN: 0005834594 *
LUKAS BUENDGENS ET AL.: ""Growth Differentiation Factor-15 Is a Predictor of Mortality in Critically Ill Patients with Sepsi", DISEASE MARKERS, vol. 2017, JPN6026013175, 2017, pages 1 - 10, ISSN: 0005834589 *
RICARDO CARPIO ET AL.: ""Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency d", CLINICA CHIMICA ACTA, vol. 450, JPN6026013185, October 2015 (2015-10-01), pages 169 - 175, ISSN: 0005834597 *
SIMON SKIBSTED ET AL.: ""Biomarkers of Endothelial Cell Activation in Early Sepsis"", SHOCK, vol. 39, no. 5, JPN6026013176, May 2013 (2013-05-01), pages 427 - 432, ISSN: 0005834590 *
YOSHIKAZU OKAMURA ET AL.: ""Development of a point-of-care assay system for measurement of presepsin (sCD14-ST)"", CLINICA CHIMICA ACTA, vol. Vol. 412, No. 23-24, JPN6026013183, November 2011 (2011-11-01), pages 2157 - 2161, ISSN: 0005834596 *

Also Published As

Publication number Publication date
WO2022229442A2 (en) 2022-11-03
CN117321419A (zh) 2023-12-29
EP4330682A2 (en) 2024-03-06
US20240230672A1 (en) 2024-07-11
WO2022229442A3 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
JP2026048754A (ja) 敗血症の早期検出用のｐｃｔマーカーパネル
JP2024516680A (ja) 敗血症の早期検出用のｉｌ６マーカーパネル
JP2024516677A (ja) 敗血症の早期検出用のｎｇａｌマーカーパネル
JP2024516678A (ja) 敗血症の早期検出用のｓｔｒｅｍ１マーカーパネル
JP2024516665A (ja) 敗血症の早期検出のためのプレセプシンマーカーパネル
JP2024516681A (ja) 敗血症の早期検出のためのｓＦｌｔ１マーカーパネル
JP2024537774A (ja) 敗血症の早期検出のためのＭＲ－ｐｒｏＡＤＭマーカーパネル
JP2025506704A (ja) 敗血症を早期検出するためのｄｌｌ１マーカーパネル
JP2024515086A (ja) 敗血症の早期検出のためのｇｄｆ１５マーカーパネル
JP2024516001A (ja) 敗血症の早期検出のためのｅｓｍ１マーカーパネル
JP2024516679A (ja) 敗血症の早期検出用のｉｇｆｂｐ７マーカーパネル

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407